{ "instance": { "epzm-20220630.htm": { "axisCustom": 1, "axisStandard": 31, "contextCount": 300, "dts": { "calculationLink": { "local": [ "epzm-20220630_cal.xml" ] }, "definitionLink": { "local": [ "epzm-20220630_def.xml" ] }, "inline": { "local": [ "epzm-20220630.htm" ] }, "labelLink": { "local": [ "epzm-20220630_lab.xml" ] }, "presentationLink": { "local": [ "epzm-20220630_pre.xml" ] }, "schema": { "local": [ "epzm-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 649, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 2, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 6 }, "keyCustom": 105, "keyStandard": 269, "memberCustom": 56, "memberStandard": 30, "nsprefix": "epzm", "nsuri": "http://www.epizyme.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_3f7ce127-2757-4b3e-bdaf-d70c0ec50dd3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Product Revenue Net", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "shortName": "Product Revenue Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_3f7ce127-2757-4b3e-bdaf-d70c0ec50dd3", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Cash", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCash", "shortName": "Cash", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Marketable Securities", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Fair Value Measurements", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Inventory", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Supplemental Balance Sheet Information", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Income Taxes", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Commitments and Contingencies", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Leases", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Collaborations and Licensing Agreements", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreements", "shortName": "Collaborations and Licensing Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Sale of Future Royalties", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyalties", "shortName": "Sale of Future Royalties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Long-Term Debt", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Stockholders' (Deficit) Equity", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquity", "shortName": "Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Stock-Based Compensation", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Loss Per Share", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShare", "shortName": "Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:BasisOfAccountingPolicyAndConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:BasisOfAccountingPolicyAndConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_684b917e-a2da-451a-ba8e-e732b3ab447f", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Product Revenue Net (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables", "shortName": "Product Revenue Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_684b917e-a2da-451a-ba8e-e732b3ab447f", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Cash (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashTables", "shortName": "Cash (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:SecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Marketable Securities (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:SecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Inventory (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Supplemental Balance Sheet Information (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Leases (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Sale of Future Royalties (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesTables", "shortName": "Sale of Future Royalties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "epzm:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Long Term Debt (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtTables", "shortName": "Long Term Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Stockholders' (Deficit) Equity (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityTables", "shortName": "Stockholders' (Deficit) Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Loss Per Share (Tables)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareTables", "shortName": "Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - The Company - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "shortName": "The Company - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:NatureOfOperations", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-5", "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-5", "lang": null, "name": "us-gaap:AmortizationOfIntangibleAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail", "shortName": "Summary of Significant Accounting Policies - Summary of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "div", "us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "div", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "epzm:RevenueOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ed1e74cb-30ac-404a-80f2-f4969f91534d", "decimals": "-3", "first": true, "lang": null, "name": "epzm:RevenueAllowanceAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Product Revenue Net - Summary of Product Revenue Allowance and Reserve Categories (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail", "shortName": "Product Revenue Net - Summary of Product Revenue Allowance and Reserve Categories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "epzm:RevenueOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ed1e74cb-30ac-404a-80f2-f4969f91534d", "decimals": "-3", "first": true, "lang": null, "name": "epzm:RevenueAllowanceAndReservesBalance", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "epzm:NumberOfCustomers", "epzm:NumberOfCustomers", "epzm:NumberOfCustomers", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_f1519986-2d2e-454c-b4eb-9747a4776e84", "decimals": "INF", "first": true, "lang": null, "name": "epzm:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "U_Customer", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Product Revenue Net - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "shortName": "Product Revenue Net - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "epzm:NumberOfCustomers", "epzm:NumberOfCustomers", "epzm:NumberOfCustomers", "span", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_f1519986-2d2e-454c-b4eb-9747a4776e84", "decimals": "INF", "first": true, "lang": null, "name": "epzm:NumberOfCustomers", "reportCount": 1, "unique": true, "unitRef": "U_Customer", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_9f333484-c829-4f7a-97d8-901aaa56f0fe", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Product Revenue Net - Schedule Of Each Customer As a Percentage Of Net Product Revenue (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "shortName": "Product Revenue Net - Schedule Of Each Customer As a Percentage Of Net Product Revenue (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_9f333484-c829-4f7a-97d8-901aaa56f0fe", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_0c55d042-3444-4592-ad38-f5438e461a00", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Product Revenue Net - Schedule Of Each Customer As a Percentage Of Accounts Receivable (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "shortName": "Product Revenue Net - Schedule Of Each Customer As a Percentage Of Accounts Receivable (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_0c55d042-3444-4592-ad38-f5438e461a00", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "shortName": "Cash - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_445bf46a-c19e-4dd6-9762-e0129b3c5fab", "decimals": "-3", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-5", "first": true, "lang": null, "name": "epzm:IncreaseDecreaseInRestrictedCash1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Cash - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "shortName": "Cash - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-5", "first": true, "lang": null, "name": "epzm:IncreaseDecreaseInRestrictedCash1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "epzm:SecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:AvailableForSaleSecuritiesAmortizedCost1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Marketable Securities - Summary of Available-for-Sale Securities Held (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail", "shortName": "Marketable Securities - Summary of Available-for-Sale Securities Held (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "epzm:SecuritiesAvailableForSaleTableTextBlock", "div", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:AvailableForSaleSecuritiesAmortizedCost1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:AvailableForSaleSecuritiesGrossRealizedGainLossNet1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Marketable Securities - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "shortName": "Marketable Securities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:AvailableForSaleSecuritiesGrossRealizedGainLossNet1", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ce0c3917-12a5-4e5d-97a3-0c01d587acc2", "decimals": "-3", "first": true, "lang": null, "name": "epzm:CashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "shortName": "Fair Value Measurements - Summary of Company's Financial Assets Recognized at Fair Value (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ce0c3917-12a5-4e5d-97a3-0c01d587acc2", "decimals": "-3", "first": true, "lang": null, "name": "epzm:CashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:InventoryRawMaterialsFifo", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Inventory - Summary of Inventory (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail", "shortName": "Inventory - Summary of Inventory (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "div", "us-gaap:InventoryDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:InventoryRawMaterialsFifo", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail", "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued Expenses (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Taxes - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "shortName": "Income Taxes - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForMergerRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:PaymentsForMergerRelatedCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ee5433f3-ba13-4f69-9c5e-10842ee9d197", "decimals": "-3", "first": true, "lang": null, "name": "epzm:MonthlyBaseRent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Leases - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "shortName": "Leases - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ee5433f3-ba13-4f69-9c5e-10842ee9d197", "decimals": "-3", "first": true, "lang": null, "name": "epzm:MonthlyBaseRent", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Leases - Summary of Lease Costs and Company's Operating Leases (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail", "shortName": "Leases - Summary of Lease Costs and Company's Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_8ce666c4-ef89-4dd5-ac92-035afeb15ee8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Leases - Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail", "shortName": "Leases - Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_8ce666c4-ef89-4dd5-ac92-035afeb15ee8", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_b0bd35aa-3f44-421d-b6bc-4d88c0b95731", "decimals": "-5", "first": true, "lang": null, "name": "epzm:RegulatoryMilestonePaymentsObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Collaborations and Licensing Agreements - Additional Information (Details)", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "shortName": "Collaborations and Licensing Agreements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_b0bd35aa-3f44-421d-b6bc-4d88c0b95731", "decimals": "-5", "first": true, "lang": null, "name": "epzm:RegulatoryMilestonePaymentsObligation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Sale of Future Royalties - Additional Information (Details)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "shortName": "Sale of Future Royalties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_c4a461eb-b2b2-415a-9c29-2883030b2641", "decimals": "-5", "lang": null, "name": "epzm:NonCashInterestExpense", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_b0bd35aa-3f44-421d-b6bc-4d88c0b95731", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "role": "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4ef40a28-ac0b-4ca7-8d11-44ec7f512366", "decimals": "-3", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "epzm:RelatedPartyLiabilityRelatedToSaleOfFutureRoyalties", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Sale of Future Royalties - Schedule of Activity of Royalty Obligation (Details)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails", "shortName": "Sale of Future Royalties - Schedule of Activity of Royalty Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "epzm:ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "div", "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_f58a2cf1-3a8f-4ee1-a9e7-b887298576fb", "decimals": "-3", "lang": null, "name": "epzm:NonCashInterestExpenseRelatedToSaleOfFutureRoyalties", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "epzm:SaleOfFutureRoyaltiesDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_f1fe7180-665f-4885-845d-0579e4121e42", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Long-Term Debt - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "shortName": "Long-Term Debt - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_f1fe7180-665f-4885-845d-0579e4121e42", "decimals": "INF", "lang": null, "name": "epzm:NumberOfQuarterlyPaymentsOfTermLoan", "reportCount": 1, "unique": true, "unitRef": "U_Installment", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Long-Term Debt - Schedule of Minimum Aggregate Future Loan Payments (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail", "shortName": "Long-Term Debt - Schedule of Minimum Aggregate Future Loan Payments (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "div", "us-gaap:LongTermDebtTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e08fef89-2773-42fd-bbe0-3c5689190e76", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Stockholders' (Deficit) Equity - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "shortName": "Stockholders' (Deficit) Equity - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "lang": "en-US", "name": "us-gaap:CommonStockVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_db54028e-5ccb-46e9-ba47-68a65bfe20a9", "decimals": "-3", "first": true, "lang": null, "name": "epzm:FairValueOfWarrantLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Stockholders (Deficit) Equity - Schedule of Fair Value of Warrant Liability (Details)", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityScheduleOfFairValueOfWarrantLiabilityDetails", "shortName": "Stockholders (Deficit) Equity - Schedule of Fair Value of Warrant Liability (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_db54028e-5ccb-46e9-ba47-68a65bfe20a9", "decimals": "-3", "first": true, "lang": null, "name": "epzm:FairValueOfWarrantLiability", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_3a2bf0ac-3edb-4806-a432-48fff2125ae6", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Stockholders (Deficit) Equity - Summary of Key Assumptions Used to Value Warrant (Details)", "role": "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "shortName": "Stockholders (Deficit) Equity - Summary of Key Assumptions Used to Value Warrant (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "div", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_3a2bf0ac-3edb-4806-a432-48fff2125ae6", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_b9b63fe9-f673-44e6-8169-f44f8438c779", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_b9b63fe9-f673-44e6-8169-f44f8438c779", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "shortName": "Stock-Based Compensation - Schedule of Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_ff7fde83-82b1-49a1-b9c8-ba58b2f561b5", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4dade53d-3f01-45bf-b7e4-ef2af89b903a", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Stock-Based Compensation - Assumptions Used in Applying Pricing Model (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail", "shortName": "Stock-Based Compensation - Assumptions Used in Applying Pricing Model (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4dade53d-3f01-45bf-b7e4-ef2af89b903a", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_db54028e-5ccb-46e9-ba47-68a65bfe20a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail", "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_db54028e-5ccb-46e9-ba47-68a65bfe20a9", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_29f6a167-0db4-4ee3-a081-71f397cfcb27", "decimals": "-3", "first": true, "lang": null, "name": "epzm:CommissionsAndOfferingCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_29f6a167-0db4-4ee3-a081-71f397cfcb27", "decimals": "-3", "first": true, "lang": null, "name": "epzm:CommissionsAndOfferingCosts", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_6286260b-2fa7-4656-918f-79b71ca9636e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Stock-Based Compensation - Summary of Service Based Restricted Stock Units (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail", "shortName": "Stock-Based Compensation - Summary of Service Based Restricted Stock Units (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_6286260b-2fa7-4656-918f-79b71ca9636e", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100710 - Disclosure - Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetail", "shortName": "Loss Per Share - Schedule of Basic and Diluted Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_4b14e920-a442-4a6a-899f-668090b22186", "decimals": "-3", "lang": null, "name": "us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100720 - Disclosure - Loss Per Share - Common Stock Equivalents from Calculation of Diluted Loss Per Share Attributable to Common Stockholders (Detail)", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail", "shortName": "Loss Per Share - Common Stock Equivalents from Calculation of Diluted Loss Per Share Attributable to Common Stockholders (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - The Company", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "epzm-20220630.htm", "contextRef": "C_e9e4efda-427d-4523-8259-9d2ac3ac8fce", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 88, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r623" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "verboseLabel": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r621" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r620" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r622" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "epzm_AccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Line Items]", "label": "Accounting Policies [Line Items]", "terseLabel": "Accounting Policies [Line Items]" } } }, "localname": "AccountingPoliciesLineItems", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_AccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting Policies [Table]", "label": "Accounting Policies [Table]", "terseLabel": "Accounting Policies [Table]" } } }, "localname": "AccountingPoliciesTable", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_AccruedResearchAndDevelopmentExpenseCurrent": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued research and development expense current.", "label": "Accrued Research And Development Expense Current", "terseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Achievement of specified levels of annual net sales of licensed products member", "label": "Achievement Of Specified Levels Of Annual Net Sales Of Licensed Products [Member]", "terseLabel": "Achievement of Specified Annual Net Sales [Member]" } } }, "localname": "AchievementOfSpecifiedLevelsOfAnnualNetSalesOfLicensedProductsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Shares", "label": "Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition Shares", "terseLabel": "Stock-based compensation, Shares" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognitionShares", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "epzm_AmendedAndRestatedAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and restated agreement.", "label": "Amended And Restated Agreement [Member]", "terseLabel": "Amended And Restated Loan Agreement [Member]" } } }, "localname": "AmendedAndRestatedAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_AmendedAndRestatedLoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amended and Restated Loan Agreement [Member]", "label": "Amended And Restated Loan Agreement [Member]", "terseLabel": "Amended And Restated Loan Agreement [Member]" } } }, "localname": "AmendedAndRestatedLoanAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_AnnualIncreaseOfBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Annual increase of base rent.", "label": "Annual Increase Of Base Rent", "terseLabel": "Annual increase of base rent" } } }, "localname": "AnnualIncreaseOfBaseRent", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecurities1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available or sale securities1.", "label": "Available For Sale Securities1", "terseLabel": "Available-For-Sale Securities Held, Fair Value" } } }, "localname": "AvailableForSaleSecurities1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities accumulated gross unrealized gain before tax1.", "label": "Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax1", "terseLabel": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities accumulated gross unrealized loss before tax1.", "label": "Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax1", "negatedLabel": "Available-For-Sale Securities Held, Gross Unrealized Losses" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecuritiesAmortizedCost1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available For Sale Securities Amortized Cost1", "label": "Available For Sale Securities Amortized Cost1", "terseLabel": "Available-For-Sale Securities Held, Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities continuous unrealized loss position less than twelve months fair value1.", "label": "Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value1", "terseLabel": "Available-for-sale securities, continuous unrealized loss position, less than twelve months, fair value" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_AvailableForSaleSecuritiesGrossRealizedGainLossNet1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Available for sale securities gross realized gain loss net.", "label": "Available For Sale Securities Gross Realized Gain Loss Net1", "terseLabel": "Realized gains (losses) recognized on sale or maturity of marketable equity securities" } } }, "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossNet1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_BMRHampshireLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bmr hampshire llc.", "label": "B M R Hampshire L L C [Member]", "terseLabel": "BMR-Hampshire LLC [Member]" } } }, "localname": "BMRHampshireLLCMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_BasisOfAccountingPolicyAndConsolidationPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of accounting policy and consolidation.", "label": "Basis Of Accounting Policy And Consolidation Policy [Text Block]", "terseLabel": "Basis of Presentation and Principles of Consolidation" } } }, "localname": "BasisOfAccountingPolicyAndConsolidationPolicyTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "epzm_BasisOfPresentationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis Of Presentation [Line Items]", "label": "Basis Of Presentation [Line Items]", "terseLabel": "Basis Of Presentation [Line Items]" } } }, "localname": "BasisOfPresentationLineItems", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_BioPharmaCreditInvestmentsVMasterLPAndBioPharmaCreditPLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioPharma Credit Investments V Master LP and BioPharma Credit PLC.", "label": "Bio Pharma Credit Investments V Master L P And Bio Pharma Credit P L C [Member]", "terseLabel": "BioPharma Credit Investments V Master LP And BioPharma Credit PLC [Member]" } } }, "localname": "BioPharmaCreditInvestmentsVMasterLPAndBioPharmaCreditPLCMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_BioPharmaCreditInvestmentsVMasterLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BioPharma Credit Investments V (Master) LP [Member].", "label": "Bio Pharma Credit Investments V Master L P [Member]", "terseLabel": "BioPharma Credit Investments V (Master) LP [Member]" } } }, "localname": "BioPharmaCreditInvestmentsVMasterLPMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_BoehringerIngelheimInternationalGmbHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boehringer Ingelheim International GmbH.", "label": "Boehringer Ingelheim International Gmb H [Member]", "terseLabel": "Boehringer Ingelheim [Member]" } } }, "localname": "BoehringerIngelheimInternationalGmbHMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_BusinessCombinationPurchaseAgreementTerminationFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination purchase agreement termination fee.", "label": "Business Combination Purchase Agreement Termination Fee", "terseLabel": "Termination fee" } } }, "localname": "BusinessCombinationPurchaseAgreementTerminationFee", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_CambridgeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cambridge.", "label": "Cambridge [Member]", "terseLabel": "Cambridge [Member]" } } }, "localname": "CambridgeMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_CashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail": { "order": 0.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value disclosure of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Equivalents Fair Value Disclosure", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsFairValueDisclosure", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "epzm_ChangeInFairValueOfWarrantLiability": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of warrant liability.", "label": "Change in Fair Value of Warrant Liability", "terseLabel": "Change in fair value of warrant liability" } } }, "localname": "ChangeInFairValueOfWarrantLiability", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_ChangeInFairValueOfWarrantsToPurchaseCommonStock": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of warrants to purchase common stock.", "label": "Change in Fair Value of Warrants to Purchase Common Stock", "terseLabel": "Change in fair value of warrants to purchase common stock" } } }, "localname": "ChangeInFairValueOfWarrantsToPurchaseCommonStock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "epzm_ChargebacksDiscountsAndFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chargebacks, discounts, and fees member.", "label": "Chargebacks Discounts And Fees [Member]", "terseLabel": "Chargebacks, Discounts, and Fees [Member]" } } }, "localname": "ChargebacksDiscountsAndFeesMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "domainItemType" }, "epzm_ClassOfWarrantOrRightDateBeforeWhichWarrantsOrRightsExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Date before which Warrants or Rights Exercisable", "label": "Class Of Warrant Or Right Date Before Which Warrants Or Rights Exercisable", "terseLabel": "Date prior to which warrants are exercisable" } } }, "localname": "ClassOfWarrantOrRightDateBeforeWhichWarrantsOrRightsExercisable", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "epzm_ClinicalDevelopmentAndRegulatoryMilestonePaymentUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical development and regulatory milestone payment under license agreement.", "label": "Clinical Development And Regulatory Milestone Payment Under License Agreement", "terseLabel": "Development and regulatory milestone payment" } } }, "localname": "ClinicalDevelopmentAndRegulatoryMilestonePaymentUnderLicenseAgreement", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ClinicalLicenseAgreementExpirationTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical license agreement expiration terms.", "label": "Clinical License Agreement Expiration Terms", "terseLabel": "Clinical license agreement expiration terms" } } }, "localname": "ClinicalLicenseAgreementExpirationTerms", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "epzm_ClinicalSalesMilestonePaymentUnderLicenseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Clinical sales milestone payment under license agreement.", "label": "Clinical Sales Milestone Payment Under License Agreement", "terseLabel": "Sales milestone payment" } } }, "localname": "ClinicalSalesMilestonePaymentUnderLicenseAgreement", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ClinicalSupplyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical supply.", "label": "Clinical Supply [Member]", "terseLabel": "Clinical Supply [Member]" } } }, "localname": "ClinicalSupplyMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_CollaborationAndOtherRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and other revenue.", "label": "Collaboration And Other Revenue [Member]", "terseLabel": "Collaboration and Other Revenue [Member]" } } }, "localname": "CollaborationAndOtherRevenueMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "epzm_CollaborationArrangementContractualObligationAssumedByPartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contractual obligations assumed by the Company's collaboration partner under the terms of the collaboration arrangement(s).", "label": "Collaboration Arrangement Contractual Obligation Assumed By Partner", "verboseLabel": "Remaining unpaid milestone payments" } } }, "localname": "CollaborationArrangementContractualObligationAssumedByPartner", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_CollaborationRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration revenue.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration Revenue [Member]" } } }, "localname": "CollaborationRevenueMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_CollaboratorTerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The period of notice a collaborator is required to provide in order to terminate a collaboration agreement.", "label": "Collaborator Termination Notice Period", "terseLabel": "Notice period in days" } } }, "localname": "CollaboratorTerminationNoticePeriod", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "epzm_CommissionProceedsFromSale": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission proceeds from sale", "label": "Commission Proceeds From Sale", "terseLabel": "Commission proceeds from sale" } } }, "localname": "CommissionProceedsFromSale", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "epzm_CommissionsAndOfferingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commissions and offering costs.", "label": "Commissions And Offering Costs", "terseLabel": "Commissions And Offering Costs" } } }, "localname": "CommissionsAndOfferingCosts", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "epzm_CommissionsOfferingCostsAndFinancingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commissions offering costs and financing costs.", "label": "Commissions Offering Costs And Financing Costs", "verboseLabel": "Proceeds from financing Costs after deducting" } } }, "localname": "CommissionsOfferingCostsAndFinancingCosts", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_CommonSharesConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares conversion ratio.", "label": "Common Shares Conversion Ratio", "terseLabel": "Common stock conversion ratio" } } }, "localname": "CommonSharesConversionRatio", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "percentItemType" }, "epzm_CommonSharesUponConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares upon conversion.", "label": "Common Shares Upon Conversion", "terseLabel": "Common stock upon conversion" } } }, "localname": "CommonSharesUponConversion", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "epzm_ContractWithCustomerLiabilityAdditions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with customer liability additions.", "label": "Contract With Customer Liability Additions", "terseLabel": "Nonrefundable upfront payment received" } } }, "localname": "ContractWithCustomerLiabilityAdditions", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ContractualContingentValueRightPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual contingent value right per share.", "label": "Contractual Contingent Value Right Per Share", "terseLabel": "Contingent payment per share" } } }, "localname": "ContractualContingentValueRightPerShare", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "epzm_ConversionOfStockNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of stock notice period.", "label": "Conversion Of Stock Notice Period", "terseLabel": "Conversion of stock notice period" } } }, "localname": "ConversionOfStockNoticePeriod", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "epzm_CostOfEstablishment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of establishment.", "label": "Cost Of Establishment", "terseLabel": "Cost of establishment" } } }, "localname": "CostOfEstablishment", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_CreditFacilityTransactionCostsIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Credit facility transaction costs incurred.", "label": "Credit Facility Transaction Costs Incurred", "terseLabel": "Transaction costs" } } }, "localname": "CreditFacilityTransactionCostsIncurred", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_CustomerFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Five Member", "label": "Customer Five Member", "terseLabel": "Customer 5 [Member]" } } }, "localname": "CustomerFiveMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "epzm_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer four member.", "label": "Customer Four [Member]", "terseLabel": "Customer 4 [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "epzm_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer one member.", "label": "Customer One [Member]", "terseLabel": "Customer 1 [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "epzm_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer three member.", "label": "Customer Three [Member]", "terseLabel": "Customer 3 [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "epzm_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer two member.", "label": "Customer Two [Member]", "terseLabel": "Customer 2 [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "epzm_DescriptionOfPrepaymentOfTrancheTermLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of prepayment of tranche term loan", "label": "Description Of Prepayment Of Tranche Term Loan", "terseLabel": "Description of prepayment of tranche term loan" } } }, "localname": "DescriptionOfPrepaymentOfTrancheTermLoan", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_EffectiveAnnualInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective annual expense rate.", "label": "Effective Annual Interest Rate", "terseLabel": "Effective annual interest Rate" } } }, "localname": "EffectiveAnnualInterestRate", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "epzm_EffectiveAnnualInterestRateOfRoyaltyPayment1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Annual Interest Rate Of Royalty Payment.", "label": "Effective Annual Interest Rate Of Royalty Payment1", "terseLabel": "Payments for Royalties" } } }, "localname": "EffectiveAnnualInterestRateOfRoyaltyPayment1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "epzm_EisaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eisai.", "label": "Eisai [Member]", "terseLabel": "Eisai [Member]" } } }, "localname": "EisaiMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan [Member]", "label": "Employee Stock Purchase Plan [Member]", "terseLabel": "Shares Issuable Under Employee Stock Purchase Plan [Member]" } } }, "localname": "EmployeeStockPurchasePlanMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "epzm_EquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity [Line Items]", "label": "Equity [Line Items]", "terseLabel": "Equity [Line Items]" } } }, "localname": "EquityLineItems", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_EquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity [Table]", "label": "Equity [Table]", "terseLabel": "Equity [Table]" } } }, "localname": "EquityTable", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_EstimatedFutureAmortizationOfIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated future amortization expense for intangible assets for the year ended.", "label": "Estimated Future Amortization Of Intangible Assets", "terseLabel": "Estimated future amortization of intangible assets" } } }, "localname": "EstimatedFutureAmortizationOfIntangibleAssets", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_EstimatedFutureAmortizationOfIntangibleAssetsThereafter": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Estimated Future Amortization Of Intangible Assets Thereafter", "label": "Estimated Future Amortization Of Intangible Assets Thereafter", "terseLabel": "Estimated future amortization of intangible assets thereafter" } } }, "localname": "EstimatedFutureAmortizationOfIntangibleAssetsThereafter", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_EstimatedVariableConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Estimated variable consideration", "label": "Estimated variable consideration", "terseLabel": "Estimated variable consideration" } } }, "localname": "EstimatedVariableConsideration", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ExecutiveAndEmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Executive and Employee.", "label": "Executive And Employee [Member]", "terseLabel": "Executive and Employee [Member]" } } }, "localname": "ExecutiveAndEmployeeMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value assets and liabilities measured on recurring basis.", "label": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "stringItemType" }, "epzm_FairValueOfWarrantLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value Of Warrant Liability", "label": "Fair Value Of Warrant Liability", "periodEndLabel": "Fair value at June 30, 2022", "periodStartLabel": "Fair value at January 1, 2022" } } }, "localname": "FairValueOfWarrantLiability", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityScheduleOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "epzm_FinancingCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Financing Cost.", "label": "Financing Cost", "terseLabel": "Financing Cost" } } }, "localname": "FinancingCost", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "epzm_FourthAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fourth amendment.", "label": "Fourth Amendment [Member]", "terseLabel": "Fourth Amendment [Member]" } } }, "localname": "FourthAmendmentMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_GoingConcernPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Going concern.", "label": "Going Concern Policy [Text Block]", "terseLabel": "Going Concern" } } }, "localname": "GoingConcernPolicyTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "epzm_GovernmentAndOtherRebatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government and other rebates member.", "label": "Government And Other Rebates [Member]", "terseLabel": "Government and Other Rebates [Member]" } } }, "localname": "GovernmentAndOtherRebatesMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "domainItemType" }, "epzm_GskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Glaxo Smith Kline.", "label": "Gsk [Member]", "terseLabel": "GSK [Member]" } } }, "localname": "GskMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_HampshireStreetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hampshire street member", "label": "Hampshire Street [Member]", "terseLabel": "Hampshire Street [Member]" } } }, "localname": "HampshireStreetMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_HutchMedLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HutchMed License Agreement.", "label": "Hutch Med License Agreement [Member]", "terseLabel": "HutchMed License Agreement [Member]" } } }, "localname": "HutchMedLicenseAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_HutchmedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HutchMed Warrants", "label": "HutchMed Warrants [Member]", "terseLabel": "HutchMed Warrant [Member]" } } }, "localname": "HutchmedWarrantsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_IncreaseDecreaseInOperatingLeaseAssets": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease assets.", "label": "Increase Decrease In Operating Lease Assets", "negatedLabel": "Operating lease assets" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssets", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_IncreaseDecreaseInRestrictedCash1": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in restricted cash1.", "label": "Increase Decrease In Restricted Cash1", "terseLabel": "Restricted Cash" } } }, "localname": "IncreaseDecreaseInRestrictedCash1", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_IncreaseInBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in base rent.", "label": "Increase In Base Rent", "terseLabel": "Increase in base rent" } } }, "localname": "IncreaseInBaseRent", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_InterestExpenseCreditFacilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expense credit facilities.", "label": "Interest Expense Credit Facilities", "terseLabel": "Interest Expense Credit Facilities" } } }, "localname": "InterestExpenseCreditFacilities", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_InventoryFinishedGoodsFifo": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail": { "order": 0.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and FIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory Finished Goods Fifo", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsFifo", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "epzm_InventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory [Member].", "label": "Inventory [Member]", "terseLabel": "Inventory" } } }, "localname": "InventoryMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "domainItemType" }, "epzm_InventoryRawMaterialsFifo": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and FIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory Raw Materials Fifo", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsFifo", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "epzm_InventoryWorkInProcessFifo": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and FIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.", "label": "Inventory Work In Process Fifo", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessFifo", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "epzm_IpsenPharmaSasMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ipsen pharma SAS.", "label": "Ipsen Pharma SAS [Member]", "terseLabel": "Ipsen Pharma SAS [Member]" } } }, "localname": "IpsenPharmaSasMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_JefferiesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jefferies LLC member", "label": "Jefferies L L C [Member]", "terseLabel": "Jefferies LLC [Member]" } } }, "localname": "JefferiesLLCMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee operating lease liability payments due after year four.", "label": "Lessee Operating Lease Liability Payments Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "epzm_LicenseAndMaterialRightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License and Material Right [Member]", "label": "License and Material Right [Member]" } } }, "localname": "LicenseAndMaterialRightMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_LicenseResearchAndDevelopmentServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License, Research and Development Service [Member]", "label": "License, Research and Development Service [Member]" } } }, "localname": "LicenseResearchAndDevelopmentServiceMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_LicenseRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License revenue.", "label": "License Revenue Member", "terseLabel": "License Revenue [Member]" } } }, "localname": "LicenseRevenueMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_LoanAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreement [Member]", "label": "Loan Agreement [Member]", "terseLabel": "Loan Agreement [Member]" } } }, "localname": "LoanAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_LoanAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loan Agreements [Member]", "label": "Loan Agreements [Member]", "terseLabel": "Loan Agreement [Member]" } } }, "localname": "LoanAgreementsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_ManufacturingMaterialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Manufacturing material.", "label": "Manufacturing Material [Member]", "terseLabel": "Manufacturing Material [Member]" } } }, "localname": "ManufacturingMaterialMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_MarketableSecuritiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Marketable securities fair value disclosure.", "label": "Marketable Securities Fair Value Disclosure", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesFairValueDisclosure", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "epzm_MilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments.", "label": "Milestone Payments", "terseLabel": "Milestone payments" } } }, "localname": "MilestonePayments", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_MonthlyBaseRent": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Monthly base rent.", "label": "Monthly Base Rent", "terseLabel": "Monthly base rent" } } }, "localname": "MonthlyBaseRent", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_NonCashInterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non cash interest expense" } } }, "localname": "NonCashInterestExpense", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non cash interest expense related to sale of future royalties.", "label": "Non Cash Interest Expense Related To Sale Of Future Royalties", "verboseLabel": "Non-cash interest expense recognized" } } }, "localname": "NonCashInterestExpenseRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_NonCashInterestExpenseRelatedToSaleOfRoyalties": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non-cash interest expense related to sale of royalties.", "label": "Non Cash Interest Expense Related To Sale Of Royalties", "terseLabel": "Non-cash interest expense associated with the sale of future royalties" } } }, "localname": "NonCashInterestExpenseRelatedToSaleOfRoyalties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_NonCashRoyaltyRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash royalty revenue.", "label": "Non Cash Royalty Revenue", "terseLabel": "Non-cash royalty revenue" } } }, "localname": "NonCashRoyaltyRevenue", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalty": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non cash royalty revenue related to sale of future royalty.", "label": "Non Cash Royalty Revenue Related To Sale Of Future Royalty", "negatedLabel": "Non-cash royalty revenue related to sale of future royalties", "terseLabel": "Non-cash royalty revenue related to sale of future royalties" } } }, "localname": "NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalty", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_NonExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non-Executive Officer Member.", "label": "Non Executive Officer [Member]", "terseLabel": "Non-Executive Officer [Member]" } } }, "localname": "NonExecutiveOfficerMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_NumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "epzm_NumberOfOptionTargets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of option targets.", "label": "Number Of Option Targets", "terseLabel": "Number of option targets" } } }, "localname": "NumberOfOptionTargets", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "epzm_NumberOfQuarterlyPaymentsOfTermLoan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Quarterly Payments Of Term Loan.", "label": "Number Of Quarterly Payments Of Term Loan", "terseLabel": "Number of quarterly payments of term loan" } } }, "localname": "NumberOfQuarterlyPaymentsOfTermLoan", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "epzm_NumberOfSecuritiesInUnrealizedLossPosition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities in unrealized loss position.", "label": "Number Of Securities In Unrealized Loss Position", "terseLabel": "Number of securities in unrealized loss position" } } }, "localname": "NumberOfSecuritiesInUnrealizedLossPosition", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "epzm_NumberOfSharesPurchasableReducedUponCondition": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares purchasable reduced upon condition.", "label": "Number of Shares Purchasable Reduced Upon Condition", "terseLabel": "Number of shares purchasable reduced upon condition" } } }, "localname": "NumberOfSharesPurchasableReducedUponCondition", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "epzm_NumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of tranches.", "label": "Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "NumberOfTranches", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "epzm_ObligationRelatedToWorldWideRoyalty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Obligation related to world wide royalty.", "label": "Obligation Related To World Wide Royalty", "verboseLabel": "Obligation related to World Wide Royalty" } } }, "localname": "ObligationRelatedToWorldWideRoyalty", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_OpenMarketSaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open market sale agreement member", "label": "Open Market Sale Agreement [Member]", "terseLabel": "ATM Sale Agreement [Member]" } } }, "localname": "OpenMarketSaleAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_OperatingCostReductionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Cost Reduction Plan.", "label": "Operating Cost Reduction Plan [Member]", "terseLabel": "Operating Cost Reduction Plan [Member]" } } }, "localname": "OperatingCostReductionPlanMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_OperatingLeaseRentExpenseIncrementalPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease rent expense incremental percentage.", "label": "Operating Lease Rent Expense Incremental Percentage", "terseLabel": "Operating lease rent expense incremental percentage" } } }, "localname": "OperatingLeaseRentExpenseIncrementalPercentage", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "epzm_OptionGrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Optiong grant date.", "label": "Option Grant Date", "terseLabel": "Grant date of option" } } }, "localname": "OptionGrantDate", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "dateItemType" }, "epzm_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxShares", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Shares", "terseLabel": "Unrealized (loss) gain on available-for-sale securities,Shares" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxShares", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "epzm_OtherRevenuePolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other revenue policy.", "label": "Other Revenue Policy [Text Block]", "terseLabel": "Other Revenue" } } }, "localname": "OtherRevenuePolicyTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "epzm_PercentageCostIncurredForGlobalStudiesAndTotalNumberOfPatientsEnrolledInTheTerritory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage cost incurred for global studies and total number of patients enrolled In the territory.", "label": "Percentage Cost Incurred For Global Studies And Total Number Of Patients Enrolled In The Territory", "terseLabel": "Percentage cost incurred for global studies and total number of patients enrolled In the territory" } } }, "localname": "PercentageCostIncurredForGlobalStudiesAndTotalNumberOfPatientsEnrolledInTheTerritory", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "epzm_PercentageCostIncurredForGlobalStudiesNotSpecificToAnyTerritory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage cost incurred for global studies not specific to any territory.", "label": "Percentage Cost Incurred For Global Studies Not Specific To Any Territory", "terseLabel": "Percentage cost incurred for global studies not specific to any territory" } } }, "localname": "PercentageCostIncurredForGlobalStudiesNotSpecificToAnyTerritory", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "epzm_PercentageOfConversionRestrictionUponHolderOfConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of conversion restriction upon holder of convertible preferred stock shares.", "label": "Percentage Of Conversion Restriction Upon Holder Of Convertible Preferred Stock", "terseLabel": "Percentage of conversion restriction upon holder of convertible preferred stock shares" } } }, "localname": "PercentageOfConversionRestrictionUponHolderOfConvertiblePreferredStock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "epzm_PercentageOfCrossFunctionalReductionOfCurrentWorkforce": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of cross-functional reduction of current workforce.", "label": "Percentage Of Cross Functional Reduction Of Current Workforce", "terseLabel": "Percentage of cross-functional reduction of current workforce" } } }, "localname": "PercentageOfCrossFunctionalReductionOfCurrentWorkforce", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "epzm_PercentageOfOwnershipInterestRelatedParties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership interest related parties.", "label": "Percentage Of Ownership Interest Related Parties", "terseLabel": "Percentage of ownership interest related parties" } } }, "localname": "PercentageOfOwnershipInterestRelatedParties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "epzm_PercentageOfSharesAtTheTimeOfExpirationOfOffer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of shares at the time of expiration of offer.", "label": "Percentage Of Shares At The Time Of Expiration Of Offer", "terseLabel": "Percentage of share" } } }, "localname": "PercentageOfSharesAtTheTimeOfExpirationOfOffer", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "epzm_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance based restricted stock units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance Based RSU [Member]" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_PotentialPaymentForAchievementOfSpecifiedMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the potential payment that may be received upon achievement of specified milestones per agreement.", "label": "Potential Payment For Achievement Of Specified Milestones", "terseLabel": "Potential milestone payments" } } }, "localname": "PotentialPaymentForAchievementOfSpecifiedMilestones", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_PrepaymentOfLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Prepayment of loan.", "label": "Prepayment Of Loan", "terseLabel": "Prepayment of loan" } } }, "localname": "PrepaymentOfLoan", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_PrincipalAndInterestDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Principal and Interest due.", "label": "Principal And Interest Due", "terseLabel": "Principal And Interest Due" } } }, "localname": "PrincipalAndInterestDue", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_ProceedFromAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceed from agreement.", "label": "Proceed From Agreement", "terseLabel": "Proceed from agreement" } } }, "localname": "ProceedFromAgreement", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ProceedsFromIssuanceOfCommonStockInConnectionWithExerciseOfProceedsFromPutOptionNetOfFinancingCosts": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from the issuance of common stock in connection with the exercise of proceeds from put option, net of financing costs.", "label": "Proceeds From Issuance Of Common Stock In Connection With Exercise Of Proceeds From Put Option Net Of Financing Costs", "terseLabel": "Proceeds from the issuance of common stock in connection with the exercise of the Put Option, net of financing costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockInConnectionWithExerciseOfProceedsFromPutOptionNetOfFinancingCosts", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_ProceedsFromSaleOfEquitySecuritiesFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of equity securities fair value.", "label": "Proceeds From Sale Of Equity Securities Fair Value", "terseLabel": "Proceeds from sale of equity securities fair value" } } }, "localname": "ProceedsFromSaleOfEquitySecuritiesFairValue", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_ProceedsFromSaleOfFutureRoyalties": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of future royalties.", "label": "Proceeds From Sale Of Future Royalties", "terseLabel": "Proceeds from sale of future royalties" } } }, "localname": "ProceedsFromSaleOfFutureRoyalties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ProductRevenueNet": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Product revenue, net.", "label": "Product Revenue Net", "terseLabel": "Product revenue, net" } } }, "localname": "ProductRevenueNet", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "epzm_PropertyAndEquipmentIncludedInAccountsPayableOrAccruals": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Property and equipment included in accounts payable or accruals.", "label": "Property And Equipment Included In Accounts Payable Or Accruals", "terseLabel": "Property and equipment included in accounts payable or accruals" } } }, "localname": "PropertyAndEquipmentIncludedInAccountsPayableOrAccruals", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_PublicOfferingCostsIncurredButNotYetPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay costs incurred related to the entity's public offering.", "label": "Public Offering Costs Incurred But Not Yet Paid", "terseLabel": "Unpaid offering costs" } } }, "localname": "PublicOfferingCostsIncurredButNotYetPaid", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "epzm_PurchaseAgreementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase agreement axis.", "label": "Purchase Agreement [Axis]", "terseLabel": "Purchase Agreement" } } }, "localname": "PurchaseAgreementAxis", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_PurchaseAgreementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase agreement domain.", "label": "Purchase Agreement [Domain]", "terseLabel": "Purchase Agreement" } } }, "localname": "PurchaseAgreementDomain", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_RPIAndAffiliatesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI and affiliates.", "label": "R P I And Affiliates [Member]", "terseLabel": "RPI and Affiliates [Member]" } } }, "localname": "RPIAndAffiliatesMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_RPIFinanceTrustAndBioPharmaCreditInvestmentsVLpAndBioPharmaCreditPLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI Finance Trust and BioPharma Credit Investments v Lp and BioPharma Credit PLC.", "label": "R P I Finance Trust And Bio Pharma Credit Investments V Lp And Bio Pharma Credit P L C [Member]", "terseLabel": "RPI Finance Trust (RPI) and BioPharma Credit Investments V (Master) LP and BioPharma Credit PLC (the Lenders) [Member]" } } }, "localname": "RPIFinanceTrustAndBioPharmaCreditInvestmentsVLpAndBioPharmaCreditPLCMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_RPIFinanceTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI finance trust member.", "label": "R P I Finance Trust [Member]", "terseLabel": "RPI Finance Trust [Member]" } } }, "localname": "RPIFinanceTrustMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_RPIPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RPI purchase agreement member.", "label": "R P I Purchase Agreement [Member]", "terseLabel": "RPI Purchase Agreement [Member]" } } }, "localname": "RPIPurchaseAgreementMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_RegulatoryMilestonePaymentsObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Regulatory milestone payments the Company has agreed to pay its collaboration partner.", "label": "Regulatory Milestone Payments Obligation", "terseLabel": "Regulatory milestone payments obligation" } } }, "localname": "RegulatoryMilestonePaymentsObligation", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ReimbursementsReceivableOfDevelopmentCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursements receivable of development costs.", "label": "Reimbursements Receivable Of Development Costs", "terseLabel": "Reimbursements receivable of development costs" } } }, "localname": "ReimbursementsReceivableOfDevelopmentCosts", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ReimbursementsReceivableOfRegulatoryMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursements receivable of regulatory milestone.", "label": "Reimbursements Receivable Of Regulatory Milestone", "terseLabel": "Reimbursements receivable of regulatory milestone" } } }, "localname": "ReimbursementsReceivableOfRegulatoryMilestone", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_ReimbursementsReceivableOfResearchAndDevelopmentCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursements Receivable Of Research and Development Cost", "label": "Reimbursements Receivable Of Research and Development Cost", "terseLabel": "Reimbursements receivable of research and development costs" } } }, "localname": "ReimbursementsReceivableOfResearchAndDevelopmentCost", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_RelatedPartyLiabilityRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails": { "order": 0.0, "parentTag": "epzm_RelatedPartyLiabilityRelatedToSaleOfFutureRoyaltiesNet", "weight": 1.0 }, "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related party liability related To sale of future royalties.", "label": "Related Party Liability Related To Sale Of Future Royalties", "terseLabel": "Related party liability related to sale of future royalties, net of current portion" } } }, "localname": "RelatedPartyLiabilityRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "epzm_RelatedPartyLiabilityRelatedToSaleOfFutureRoyaltiesNet": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Related Party Liability Related To Sale Of Future Royalties, Net", "label": "Related Party Liability Related To Sale Of Future Royalties, Net", "totalLabel": "Related party liability related to sale of future royalties, net of current portion" } } }, "localname": "RelatedPartyLiabilityRelatedToSaleOfFutureRoyaltiesNet", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_RelatedPartyNonCashInterestExpenseRelatedToSaleOfFutureRoyalties": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party non cash interest expense related to sale of future royalties.", "label": "Related Party Non Cash Interest Expense Related To Sale Of Future Royalties", "negatedLabel": "Related party non-cash interest expense related to sale of future royalties" } } }, "localname": "RelatedPartyNonCashInterestExpenseRelatedToSaleOfFutureRoyalties", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "epzm_ResearchAndDevelopmentLicenseAgreementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development, license agreement date.", "label": "Research And Development License Agreement Date", "terseLabel": "License agreement date" } } }, "localname": "ResearchAndDevelopmentLicenseAgreementDate", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "epzm_ResearchAndDevelopmentObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and Development Obligation [Member]", "label": "Research and Development Obligation [Member]" } } }, "localname": "ResearchAndDevelopmentObligationMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_RestrictedCashAndOtherAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted cash and other assets [Member].", "label": "Restricted Cash And Other Assets [Member]", "terseLabel": "Restricted Cash And Other Assets" } } }, "localname": "RestrictedCashAndOtherAssetsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "domainItemType" }, "epzm_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units.", "label": "Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_ReturnsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Returns member.", "label": "Returns [Member]", "terseLabel": "Returns [Member]" } } }, "localname": "ReturnsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "domainItemType" }, "epzm_RevenueAllowanceAndReservesBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue allowance and reserves balance.", "label": "Revenue Allowance And Reserves Balance", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "RevenueAllowanceAndReservesBalance", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "monetaryItemType" }, "epzm_RevenueAllowanceAndReservesProvision": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue allowance and reserves provision.", "label": "Revenue Allowance And Reserves Provision", "terseLabel": "Provision" } } }, "localname": "RevenueAllowanceAndReservesProvision", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "monetaryItemType" }, "epzm_RevenueAllowancesAndReservesDeductions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue allowances and reserves deductions.", "label": "Revenue Allowances And Reserves Deductions", "negatedLabel": "Payments or credits" } } }, "localname": "RevenueAllowancesAndReservesDeductions", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "monetaryItemType" }, "epzm_RevenueOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue of product revenue allowance and reserve categories table text block.", "label": "Revenue Of Product Revenue Allowance And Reserve Categories Table [Text Block]", "terseLabel": "Summary of Product Revenue Allowance and Reserve Categories" } } }, "localname": "RevenueOfProductRevenueAllowanceAndReserveCategoriesTableTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "textBlockItemType" }, "epzm_RightToRequestForAdditionalLoanAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right to request for additional loan amount.", "label": "Right To Request For Additional Loan Amount", "terseLabel": "Right to request for additional loan amount" } } }, "localname": "RightToRequestForAdditionalLoanAmount", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_RightToSellCommonShareValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right to sell common share value.", "label": "Right To Sell Common Share Value", "terseLabel": "Obligation to purchase common stock" } } }, "localname": "RightToSellCommonShareValue", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_RightToSellSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to sell share price.", "label": "Right To Sell Share Price", "terseLabel": "Obligation to purchase share price" } } }, "localname": "RightToSellSharePrice", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "epzm_RocheMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Roche.", "label": "Roche [Member]", "terseLabel": "Roche [Member]" } } }, "localname": "RocheMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_RoyaltiesPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalties payable.", "label": "Royalties Payable", "verboseLabel": "Royalties payable" } } }, "localname": "RoyaltiesPayable", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_RoyaltiesPayableForLicensedProductDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties payable for licensed product , description.", "label": "Royalties Payable For Licensed Product Description", "terseLabel": "Royalties payable for licensed product, description" } } }, "localname": "RoyaltiesPayableForLicensedProductDescription", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "epzm_SaleOfFutureRoyaltiesCurrent": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails": { "order": 1.0, "parentTag": "epzm_RelatedPartyLiabilityRelatedToSaleOfFutureRoyaltiesNet", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale of Future Royalties Current", "label": "Sale of Future Royalties Current", "terseLabel": "Less current portion" } } }, "localname": "SaleOfFutureRoyaltiesCurrent", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_SaleOfFutureRoyaltiesDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for sale of future royalties.", "label": "Sale Of Future Royalties Disclosure [Text Block]", "terseLabel": "Sale of Future Royalties" } } }, "localname": "SaleOfFutureRoyaltiesDisclosureTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyalties" ], "xbrltype": "textBlockItemType" }, "epzm_ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of activity within liability related to sale of future royalties.", "label": "Schedule Of Activity Within Liability Related To Sale Of Future Royalties Table [Text Block]", "terseLabel": "Schedule of Activity of Royalty Obligation" } } }, "localname": "ScheduleOfActivityWithinLiabilityRelatedToSaleOfFutureRoyaltiesTableTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesTables" ], "xbrltype": "textBlockItemType" }, "epzm_ScheduleOfBasisOfPresentationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Basis Of Presentation [Table]", "label": "Schedule Of Basis Of Presentation [Table]", "terseLabel": "Schedule Of Basis Of Presentation [Table]" } } }, "localname": "ScheduleOfBasisOfPresentationTable", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "epzm_SecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Securities Available For Sale [Table Text Block]", "label": "Securities Available For Sale [Table Text Block]", "terseLabel": "Summary of Available-for-Sale Securities Held" } } }, "localname": "SecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "epzm_SeriesAConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series A convertible preferred stock.", "label": "Series A Convertible Preferred Stock [Member]", "terseLabel": "Series A Convertible Preferred Stock [Member]" } } }, "localname": "SeriesAConvertiblePreferredStockMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "epzm_ServiceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service based restricted stock units.", "label": "Service Based Restricted Stock Units [Member]", "terseLabel": "Service Based RSU [Member]" } } }, "localname": "ServiceBasedRestrictedStockUnitsMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "domainItemType" }, "epzm_ShareBasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation award tranche four.", "label": "Share Based Compensation Award Tranche Four [Member]", "terseLabel": "Vest on June 30, 2020 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheFourMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_SharesOptionToSellExercisedByUnderwriters": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares option to sell exercised by underwriters.", "label": "Shares Option To Sell Exercised By Underwriters", "terseLabel": "Shares option to sell exercised by underwriters" } } }, "localname": "SharesOptionToSellExercisedByUnderwriters", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "epzm_SignedAmendmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Signed Amendment.", "label": "Signed Amendment [Member]", "terseLabel": "Signed Amendment [Member]" } } }, "localname": "SignedAmendmentMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies Policy [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "epzm_TAZVERIKMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tazverik member.", "label": "T A Z V E R I K [Member]", "terseLabel": "TAZVERIK [Member]" } } }, "localname": "TAZVERIKMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "domainItemType" }, "epzm_TazemetostatMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tazemetostat [Member]", "label": "Tazemetostat [Member]" } } }, "localname": "TazemetostatMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TazemetostatOfESAndFLMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tazemetostat of ES and FL.", "label": "Tazemetostat Of E S And F L [Member]", "terseLabel": "Tazemetostat Drug Pruducts [Member]" } } }, "localname": "TazemetostatOfESAndFLMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_TechnologySquareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Technology square member", "label": "Technology Square [Member]", "terseLabel": "Technology Square [Member]" } } }, "localname": "TechnologySquareMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_TerminationNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Termination notice period.", "label": "Termination Notice Period", "terseLabel": "Termination notice period" } } }, "localname": "TerminationNoticePeriod", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "epzm_TrancheANotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche 'A' note payable member.", "label": "Tranche A Note Payable [Member]", "terseLabel": "First Tranche [Member]" } } }, "localname": "TrancheANotePayableMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TrancheBNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche 'B' note payable member.", "label": "Tranche B Note Payable [Member]", "terseLabel": "Second Tranche [Member]" } } }, "localname": "TrancheBNotePayableMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TrancheCNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche 'C' note payable member.", "label": "Tranche C Note Payable [Member]", "terseLabel": "Third Tranche [Member]" } } }, "localname": "TrancheCNotePayableMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TrancheDNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche D note payable member.", "label": "Tranche D Note Payable [Member]", "terseLabel": "Fourth Tranche [Member]" } } }, "localname": "TrancheDNotePayableMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TrancheTermLoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tranche term loan member.", "label": "Tranche Term Loan [Member]", "terseLabel": "Tranche Term Loan [Member]" } } }, "localname": "TrancheTermLoanMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "epzm_TransactionPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction price.", "label": "Transaction Price", "terseLabel": "Total transaction price" } } }, "localname": "TransactionPrice", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_TransactionPriceRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Transaction price recognized.", "label": "Transaction Price Recognized", "terseLabel": "Transaction price recognized" } } }, "localname": "TransactionPriceRecognized", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_TwoThousandThirteenEmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Thousand Thirteen Employee Stock Purchase Plan Member", "label": "Two Thousand Thirteen Employee Stock Purchase Plan Member", "terseLabel": "2013 Employee Stock Purchase Plan [Member]" } } }, "localname": "TwoThousandThirteenEmployeeStockPurchasePlanMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_UpfrontMilestone": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Upfront milestone.", "label": "Upfront Milestone", "terseLabel": "Upfront milestone" } } }, "localname": "UpfrontMilestone", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "epzm_UpfrontPayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront Payments.", "label": "Upfront Payments", "terseLabel": "Upfront payments" } } }, "localname": "UpfrontPayments", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_VestingPeriodOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period One.", "label": "Vesting Period One [Member]", "terseLabel": "Vesting Period 1 [Member]" } } }, "localname": "VestingPeriodOneMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_VestingPeriodThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period Three [Member]", "label": "Vesting Period Three [Member]", "terseLabel": "Vesting Period 3 [Member]" } } }, "localname": "VestingPeriodThreeMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_VestingPeriodTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vesting Period Two.", "label": "Vesting Period Two [Member]", "terseLabel": "Vesting Period 2 [Member]" } } }, "localname": "VestingPeriodTwoMember", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "epzm_WarrantLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant liability", "label": "Warrant liability", "terseLabel": "Warrant liability" } } }, "localname": "WarrantLiability", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "epzm_WarrantsToExerciseCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to exercise common stock.", "label": "Warrants To Exercise Common Stock", "verboseLabel": "Warrants to exercise common stock" } } }, "localname": "WarrantsToExerciseCommonStock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "epzm_WarrantsToPurchaseCommonStock": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants to purchase common stock", "label": "Warrants to purchase common stock", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantsToPurchaseCommonStock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "epzm_WarrantsToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants to purchase shares of common stock.", "label": "Warrants To Purchase Shares Of Common Stock", "terseLabel": "Warrants to purchase shares of common stock" } } }, "localname": "WarrantsToPurchaseSharesOfCommonStock", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "epzm_WeightedAverageMaturityPeriodOfAvailableForSaleSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average maturity period of available for sale securities.", "label": "Weighted Average Maturity Period Of Available For Sale Securities", "terseLabel": "Weighted average maturity period" } } }, "localname": "WeightedAverageMaturityPeriodOfAvailableForSaleSecurities", "nsuri": "http://www.epizyme.com/20220630", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r49", "r51", "r113", "r114", "r257", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]", "terseLabel": "Executives and employees [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r185", "r327", "r332", "r572" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r256", "r282", "r345", "r347", "r491", "r492", "r493", "r494", "r495", "r496", "r515", "r569", "r573", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r256", "r282", "r345", "r347", "r491", "r492", "r493", "r494", "r495", "r496", "r515", "r569", "r573", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r185", "r327", "r332", "r572" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r182", "r327", "r330", "r519", "r568", "r570" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r182", "r327", "r330", "r519", "r568", "r570" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r256", "r282", "r334", "r345", "r347", "r491", "r492", "r493", "r494", "r495", "r496", "r515", "r569", "r573", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r256", "r282", "r334", "r345", "r347", "r491", "r492", "r493", "r494", "r495", "r496", "r515", "r569", "r573", "r617", "r618" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r50", "r51", "r113", "r114", "r257", "r283" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r183", "r184", "r327", "r331", "r571", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r183", "r184", "r327", "r331", "r571", "r605", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r186", "r479" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "terseLabel": "Title of Individual" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Line Items]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureLineItems", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "stringItemType" }, "srt_ValuationAndQualifyingAccountsDisclosureTable": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]", "terseLabel": "Valuation And Qualifying Accounts Disclosure [Table]" } } }, "localname": "ValuationAndQualifyingAccountsDisclosureTable", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r32", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r606" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r18", "r187", "r188" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r97" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of discount on investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current [Abstract]" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r9", "r36" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional services and other" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrent": { "auth_ref": [ "r7", "r9", "r36" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Royalties, Current", "terseLabel": "Current portion of liability related to the sale of future royalties" } } }, "localname": "AccruedRoyaltiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r55", "r56", "r57", "r558", "r578", "r579" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive (loss) income", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r54", "r57", "r63", "r64", "r65", "r122", "r123", "r124", "r413", "r574", "r575", "r634" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r382", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "periodEndLabel": "Additional Paid in Capital, Ending Balance", "periodStartLabel": "Additional Paid in Capital, Beginning Balance", "terseLabel": "Additional paid-in capital", "totalLabel": "Additional Paid in Capital, Total" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r122", "r123", "r124", "r379", "r380", "r381", "r430" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": { "auth_ref": [ "r297", "r304" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.", "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs", "negatedLabel": "Offering costs", "terseLabel": "Additional paid in capital, common stock" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r349", "r375", "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Compensation expense was recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r76", "r96", "r269", "r457" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r96", "r224", "r229" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of Intangible Assets", "totalLabel": "Amortization of Intangible Assets, Total" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common stock equivalents excluded from the calculation of diluted loss per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r108", "r172", "r175", "r180", "r209", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r409", "r414", "r448", "r481", "r483", "r537", "r555" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r48", "r108", "r209", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r409", "r414", "r448", "r481", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r433" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r350", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r418", "r421" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r344", "r346" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r344", "r346", "r402", "r403" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r30", "r98" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 }, "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance", "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.", "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCash" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash And Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents, and marketable securities", "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r89", "r98", "r100" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance", "periodStartLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the condensed consolidated statements of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r89", "r98", "r100" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r89", "r449" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net decrease in cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r105", "r108", "r137", "r138", "r139", "r141", "r143", "r152", "r153", "r154", "r209", "r242", "r246", "r247", "r248", "r251", "r252", "r280", "r281", "r285", "r289", "r448", "r625" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r305", "r348" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of securities into which the class of warrant or right may be converted" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r404", "r405", "r407" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations and Licensing Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Royalty Pharma and Pharmakon Advisors [Member]", "verboseLabel": "Royalty Pharma [Member]" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r41", "r237", "r540", "r562" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r234", "r235", "r236", "r238", "r607" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r122", "r123", "r430" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Aggregate common stock shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "totalLabel": "Common Stock, Shares, Issued, Total" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "periodEndLabel": "Common Stock, Value, Issued, Ending Balance", "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance", "terseLabel": "Common stock, $0.0001 par value; 450,000 shares and 225,000 shares authorized, respectively; 168,365 shares and 106,098 shares issued and outstanding, respectively", "totalLabel": "Common Stock, Value, Issued, Total" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockVotingRights": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Common Stock, Voting Rights", "terseLabel": "Number of votes for each share of common stock" } } }, "localname": "CommonStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r59", "r61", "r62", "r69", "r543", "r564" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r162", "r163", "r185", "r445", "r446", "r606" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r162", "r163", "r185", "r445", "r446", "r582", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r162", "r163", "r185", "r445", "r446", "r582", "r606" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r162", "r163", "r185", "r445", "r446" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r160", "r162", "r163", "r164", "r445", "r447", "r606" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r162", "r163", "r185", "r445", "r446", "r606" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r307", "r308", "r328" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Deferred revenue", "totalLabel": "Contract with Customer, Liability, Total" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r307", "r308", "r328" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Current portion of deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r307", "r308", "r328" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r15", "r16", "r292", "r298", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible Preferred Stock, Shares Issued upon Conversion", "terseLabel": "Number of common shares convertible for each share of convertible preferred stock" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CorporateNoteSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about short-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest).", "label": "Corporate Note Securities [Member]", "terseLabel": "Corporate Notes [Member]" } } }, "localname": "CorporateNoteSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r73", "r108", "r209", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r448" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue", "totalLabel": "Cost of Revenue, Total" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r72" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditConcentrationRiskMember": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that a specified receivable or amount at risk from a counterparty under a contractual arrangement is to a specified benchmark, such as total receivables, net revenues, pretax results. Risk is the materially adverse effects of loss attributable to (a) the failure to collect a significant receivable from a major customer or group of homogeneous accounts, or (b) a failure by a counterparty to perform under terms of a contractual arrangement.", "label": "Credit Concentration Risk [Member]", "terseLabel": "Credit Concentration Risk [Member]" } } }, "localname": "CreditConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfAccountsReceivableDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r109", "r391", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense (Benefit)", "terseLabel": "Federal income tax provision or benefit" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r109", "r391", "r396" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State and Local Tax Expense (Benefit)", "terseLabel": "State income tax provision or benefit" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r161", "r185" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r14", "r271", "r538", "r554" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-term Debt, Gross", "totalLabel": "Total minimum payments" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentCovenantDescription": { "auth_ref": [ "r14", "r552" ], "lang": { "en-us": { "role": { "documentation": "Description of minimum financial levels (for example, tangible net worth and working capital) and achievement of certain financial ratios (for example, working capital ratio and debt service coverage ratio), and adherence to certain clauses which generally require or restrict certain actions (for example, entering into a debt arrangement with equal or greater seniority, and selling or discontinuing a certain business segment or material subsidiary) to be in compliance with the covenant clauses of the debt agreement. May also include a discussion of the adverse consequences that would result if the entity violates or fails to satisfy the covenants.", "label": "Debt Instrument, Covenant Description", "terseLabel": "Debt instrument, covenant description" } } }, "localname": "DebtInstrumentCovenantDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r253", "r273", "r274", "r458", "r460", "r461" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Aggregate principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r38", "r254" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate of loan" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentInterest": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to interest.", "label": "Debt Instrument, Periodic Payment, Interest", "terseLabel": "Debt instrument outstanding interest only payment" } } }, "localname": "DebtInstrumentPeriodicPaymentInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r39", "r107", "r115", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r273", "r274", "r275", "r276", "r298", "r301", "r302", "r303", "r457", "r458", "r460", "r461", "r553" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r260", "r457", "r461" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Debt Instrument, Unamortized Discount", "negatedLabel": "Less amounts representing interest and discount", "totalLabel": "Debt Instrument, Unamortized Discount, Total" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": { "auth_ref": [ "r202", "r217" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "terseLabel": "Available-for-sale securities, continuous unrealized loss position, 12 months or longer, aggregate loss" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r31", "r260", "r459" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "terseLabel": "Issuance cost", "totalLabel": "Debt Issuance Costs, Net, Total" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date.", "label": "Deferred Revenue Arrangement, by Type [Table]", "terseLabel": "Deferred Revenue Arrangement By Type [Table]" } } }, "localname": "DeferredRevenueArrangementByTypeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Revenue Arrangement [Line Items]", "terseLabel": "Deferred Revenue Arrangement [Line Items]" } } }, "localname": "DeferredRevenueArrangementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of deferred revenue arrangement.", "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type" } } }, "localname": "DeferredRevenueArrangementTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized.", "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredRevenueArrangementTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredRevenueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue Disclosure [Abstract]" } } }, "localname": "DeferredRevenueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DemutualizationByInsuranceEntitySecuritiesIssuedOfferingCosts": { "auth_ref": [ "r581" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of offering shares or units in an insurance entity stock offering in connection with its conversion from a mutual form of ownership to a stock entity.", "label": "Demutualization by Insurance Entity, Securities Issued, Offering Costs", "terseLabel": "Company common stock aggregate offering price" } } }, "localname": "DemutualizationByInsuranceEntitySecuritiesIssuedOfferingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r96", "r230" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r51", "r419", "r420", "r423", "r425" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r70", "r127", "r128", "r129", "r130", "r131", "r135", "r137", "r141", "r142", "r143", "r147", "r148", "r431", "r432", "r544", "r565" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "totalLabel": "Earnings Per Share, Basic, Total", "verboseLabel": "Loss per share allocable to common stockholders, Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "totalLabel": "Earnings Per Share, Basic and Diluted, Total", "verboseLabel": "Basic and diluted loss per share allocable to common stockholders" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net loss per share attributable to common stockholders:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r70", "r127", "r128", "r129", "r130", "r131", "r137", "r141", "r142", "r143", "r147", "r148", "r431", "r432", "r544", "r565" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "totalLabel": "Earnings Per Share, Diluted, Total", "verboseLabel": "Loss per share allocable to common stockholders, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r144", "r145", "r146", "r149" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation and benefits", "totalLabel": "Employee-related Liabilities, Current, Total" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationScheduleOfAccruedExpensesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Expected weighted average period for recognition of compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r376" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Employee Stock Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r63", "r64", "r65", "r122", "r123", "r124", "r126", "r132", "r134", "r151", "r210", "r297", "r304", "r379", "r380", "r381", "r392", "r393", "r430", "r450", "r451", "r452", "r453", "r454", "r455", "r574", "r575", "r576", "r634" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FIFOInventoryAmount": { "auth_ref": [ "r10" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of FIFO (first in first out) inventory present at the reporting date when inventory is also valued using different valuation methods.", "label": "FIFO Inventory Amount", "terseLabel": "Inventory", "totalLabel": "Total" } } }, "localname": "FIFOInventoryAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r96", "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Decrease in fair value", "terseLabel": "Change in fair value of warrants to purchase common stock", "verboseLabel": "Decrease in fair value" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityScheduleOfFairValueOfWarrantLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r433", "r434", "r435", "r442" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r436" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Summary of Key Assumptions Used to Value Warrant" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r262", "r273", "r274", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r434", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r433", "r434", "r437", "r438", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r262", "r335", "r336", "r341", "r343", "r434", "r488" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r262", "r273", "r274", "r335", "r336", "r341", "r343", "r434", "r489" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r262", "r273", "r274", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r434", "r490" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r262", "r273", "r274", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r343", "r488", "r489", "r490" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r440", "r443" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": { "auth_ref": [ "r439", "r441" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of Change in Fair Value of Warrant Liability" } } }, "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r199", "r200", "r206", "r207", "r208", "r211", "r212", "r213", "r214", "r215", "r216", "r218", "r219", "r220", "r270", "r295", "r428", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Estimated useful life (years)" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r228" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r228", "r521" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail": { "order": 0.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "In-licensed rights", "totalLabel": "Finite-Lived Intangible Assets, Gross, Total" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r228", "r520" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Finite-Lived Intangible Assets, Net, Ending Balance", "periodStartLabel": "Finite-Lived Intangible Assets, Net, Beginning Balance", "terseLabel": "Intangible assets, net", "totalLabel": "Total intangible asset, net" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r422" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Non cash gains due to adjustment of warrant liability", "totalLabel": "Gain (Loss) on Fair Value Hedges Recognized in Earnings, Total" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r96" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment", "totalLabel": "Gain (Loss) on Disposition of Property Plant Equipment, Total" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "auth_ref": [ "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.", "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Intangible Assets, Net" } } }, "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r67", "r172", "r174", "r176", "r179", "r181", "r534", "r541", "r546", "r566" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss before income taxes", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r110", "r388", "r389", "r390", "r394", "r397", "r399", "r400", "r401" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r111", "r133", "r134", "r171", "r387", "r395", "r398", "r567" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax provision", "terseLabel": "Income tax provision", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r92", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "totalLabel": "Increase (Decrease) in Accrued Liabilities, Total" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r95", "r516" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory, current and noncurrent", "terseLabel": "Inventory, current and noncurrent", "totalLabel": "Increase (Decrease) in Inventories, Total" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "negatedLabel": "Other assets and liabilities" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InitialOfferingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A description of the time period when the company made its initial offering of a class of securities.", "label": "Initial Offering Period", "terseLabel": "Initial public offering completion date" } } }, "localname": "InitialOfferingPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r545" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest Income (Expense), Net", "terseLabel": "Interest expense , net", "totalLabel": "Interest Income (Expense), Net, Total" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r87", "r91", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateFloorMember": { "auth_ref": [ "r424" ], "lang": { "en-us": { "role": { "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount.", "label": "Interest Rate Floor [Member]", "terseLabel": "Interest Rate Floor [Member]" } } }, "localname": "InterestRateFloorMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryClassificationByIndustryGrossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory, Classification by Industry, Gross [Abstract]", "terseLabel": "Balance sheet classification" } } }, "localname": "InventoryClassificationByIndustryGrossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r223" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "totalLabel": "Inventory, Noncurrent, Total", "verboseLabel": "Total" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r10", "r44", "r102", "r150", "r221", "r222", "r223", "r517" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r598", "r599", "r600", "r601", "r602", "r603" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r205", "r535", "r550", "r604", "r632" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Operating Leases, Rent Expense", "terseLabel": "Operating lease rent expense", "totalLabel": "Operating Leases, Rent Expense, Total" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r473", "r475" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Lease Costs and Company's Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToTerminate": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether lessee has option to terminate operating lease.", "label": "Lessee, Operating Lease, Existence of Option to Terminate [true false]", "terseLabel": "Operating Lease, existence of option to terminate" } } }, "localname": "LesseeOperatingLeaseExistenceOfOptionToTerminate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "booleanItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedDescription": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Description of lessee's operating lease that has not yet commenced. Including, but not limited to, nature of involvement with construction or design of underlying asset for lease.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Description", "terseLabel": "Operating lease description" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend", "terseLabel": "Operating lease extend description" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Operating lease initial term from commencement date" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r474" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments Under Non-Cancelable Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail2": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r474" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail2": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of Credit [Member]" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r108", "r209", "r448", "r483", "r539", "r560" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r37", "r108", "r209", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r410", "r414", "r415", "r448", "r481", "r482", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r33", "r107" ], "lang": { "en-us": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Commitment Fee Amount", "terseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityCommitmentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.", "label": "Line of Credit Facility, Commitment Fee Percentage", "terseLabel": "Percentage of commitment fee paid" } } }, "localname": "LineOfCreditFacilityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r33", "r107" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line Of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r33", "r107" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line Of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r261", "r272", "r273", "r274", "r538", "r556" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Related party long-term debt, net of debt discount", "totalLabel": "Long-term debt, net of current portion" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 0.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Less current portion", "totalLabel": "Long-term Debt, Current Maturities, Total" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r115", "r240", "r265" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r115", "r240", "r265" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 4.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2026" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r115", "r240", "r265" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 3.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r115", "r240", "r265" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r115" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail": { "order": 0.0, "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r39", "r241" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r4", "r35" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "totalLabel": "Marketable Securities, Current, Total" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaturitiesOfLongTermDebtAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturities of Long-term Debt [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "MaturitiesOfLongTermDebtAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtScheduleOfMinimumAggregateFutureLoanPaymentsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r155", "r168" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "The Company" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompany" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r94", "r97" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r58", "r60", "r65", "r68", "r97", "r108", "r125", "r127", "r128", "r129", "r130", "r133", "r134", "r140", "r172", "r174", "r176", "r179", "r181", "r209", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r432", "r448", "r542", "r563" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r75" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCashFlowsDirectMethodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Cash Flows, Direct Method [Abstract]" } } }, "localname": "OperatingCashFlowsDirectMethodAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r172", "r174", "r176", "r179", "r181" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r468", "r475" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r463" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNoncancelableOperatingLeasesDetail2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total operating lease liabilities at March 31, 2022", "totalLabel": "Operating Lease, Liability, Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesScheduleOfFutureMinimumLeasePaymentsUnderNonCancelableOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r463" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease obligation" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r463" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease obligation, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r464", "r470" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows used for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r462" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r472", "r475" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r471", "r475" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeAxis": { "auth_ref": [ "r279", "r426", "r427", "r429" ], "lang": { "en-us": { "role": { "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.", "label": "Option Indexed to Issuer's Equity, Type [Axis]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_OptionIndexedToIssuersEquityTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding.", "label": "Option Indexed to Issuer's Equity, Type [Domain]", "terseLabel": "Option Indexed to Issuer's Equity, Type" } } }, "localname": "OptionIndexedToIssuersEquityTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r31" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Restricted cash and other assets", "totalLabel": "Other Assets, Noncurrent, Total" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r53", "r55" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized (loss) gain on available-for-sale securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "totalLabel": "Other Liabilities, Noncurrent, Total" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other (expense) income, net:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net", "terseLabel": "Other expense (income), net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other Receivables", "terseLabel": "Other Receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForMergerRelatedCosts": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.", "label": "Payments for Merger Related Costs", "terseLabel": "Payments for Merger Related Costs" } } }, "localname": "PaymentsForMergerRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "auth_ref": [ "r79", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.", "label": "Payments for (Proceeds from) Tenant Allowance", "terseLabel": "Tenant Allowance" } } }, "localname": "PaymentsForProceedsFromTenantAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r85" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r86" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "negatedLabel": "Payment of offering costs", "verboseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r77", "r80", "r196" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of available-for-sale securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r81" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r350", "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockLiquidationPreference": { "auth_ref": [ "r16", "r105", "r285", "r298", "r299" ], "lang": { "en-us": { "role": { "documentation": "The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.", "label": "Preferred Stock, Liquidation Preference Per Share", "terseLabel": "Liquidation preference per share" } } }, "localname": "PreferredStockLiquidationPreference", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16", "r280" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16", "r280" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "totalLabel": "Preferred Stock, Shares Issued, Total" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance", "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance", "terseLabel": "Preferred stock, $0.0001 par value; 5,000 shares authorized; 0 shares and 338 shares issued and outstanding, respectively (equivalent to 0 shares and to 3,378 shares of common stock upon conversion at a 10:1 ratio)", "totalLabel": "Preferred Stock, Value, Issued, Total" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r16", "r298" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred Stock, Voting Rights", "terseLabel": "Preferred stock, voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r28", "r29" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCollaborators": { "auth_ref": [ "r90" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from collaborators during the current period.", "label": "Proceeds from Collaborators", "terseLabel": "Fund received from collaborators" } } }, "localname": "ProceedsFromCollaborators", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r83" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net of commissions", "verboseLabel": "Proceeds from issuance of common stock, net of commissions" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r84" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from Issuance of Debt", "terseLabel": "Proceeds from the issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Debt financing received through loan agreement", "totalLabel": "Proceeds from Issuance of Long-term Debt, Total" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.", "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock", "terseLabel": "Proceeds from sale of redeemable convertible preferred stock" } } }, "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "auth_ref": [ "r83", "r378" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised", "terseLabel": "Proceeds from the issuance of shares under employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r83" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r83" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from Issuance or Sale of Equity", "terseLabel": "Aggregate fund, amount", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r84" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from Notes Payable", "terseLabel": "Non-equity funding through collaboration agreement", "totalLabel": "Proceeds from Notes Payable, Total" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r77", "r78", "r196" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale", "terseLabel": "Maturities of available-for-sale securities", "totalLabel": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale, Total" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r83", "r378" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from stock options exercised" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]", "terseLabel": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r330" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r58", "r60", "r65", "r88", "r108", "r125", "r133", "r134", "r172", "r174", "r176", "r179", "r181", "r209", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r408", "r411", "r412", "r416", "r417", "r432", "r448", "r546" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r231", "r483", "r551", "r561" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance", "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance", "terseLabel": "Property and equipment, net", "totalLabel": "Property, Plant and Equipment, Net, Total" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PutOptionMember": { "auth_ref": [ "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-us": { "role": { "documentation": "A financial contract between two parties, the buyer and the seller (writer) of the option, where the buyer has the right but not the obligation to sell a commodity or financial instrument (the underlying instrument) to the seller (writer) at a certain time for a certain price (the strike price). The seller (writer) has the obligation to purchase the underlying asset at that strike price, if the buyer exercises the option.", "label": "Put Option [Member]", "terseLabel": "Put Option [Member]" } } }, "localname": "PutOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r342", "r477", "r478" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r342", "r477", "r480", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r386", "r518", "r619" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development", "totalLabel": "Research and Development Expense, Total" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r100", "r536", "r557" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted cash, as part of other assets", "totalLabel": "Restricted Cash, Total" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r304", "r382", "r483", "r559", "r577", "r579" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance", "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance", "terseLabel": "Accumulated deficit", "totalLabel": "Retained Earnings (Accumulated Deficit), Total" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r122", "r123", "r124", "r126", "r132", "r134", "r210", "r379", "r380", "r381", "r392", "r393", "r430", "r574", "r576" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r169", "r170", "r173", "r177", "r178", "r182", "r183", "r185", "r326", "r327", "r519" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration and other revenue", "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total", "verboseLabel": "Total revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r103", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r333" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r309", "r310", "r311", "r312", "r313", "r314", "r316", "r317", "r329", "r333" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Product Revenue Net" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Cost of Revenues" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r66", "r108", "r169", "r170", "r173", "r177", "r178", "r182", "r183", "r185", "r209", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r448", "r546" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyArrangementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Category of deferred revenue by arrangement wherein certain rights are granted to exploit one or more products, under which royalties received are taken into income as revenue recognition criteria are met.", "label": "Royalty Arrangement [Member]", "terseLabel": "Royalty Purchase Agreement [Member]" } } }, "localname": "RoyaltyArrangementMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesScheduleOfActivityOfRoyaltyObligationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Sale of stock, consideration received on transaction" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Common stock shares issued" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Sale of common stock, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r162", "r185" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Net Product Revenue [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetScheduleOfEachCustomerAsPercentageOfNetProductRevenueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r144" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Stock Equivalents Excluded from Calculation of Diluted Loss Per Share Attributable to Common Stockholders" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r197", "r198", "r201", "r202", "r203", "r204", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule Of Available For Sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule Of Cash And Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Basic and Diluted Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r349", "r374", "r384" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r349", "r374", "r384" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r433", "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Company's Financial Assets Recognized at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r225", "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Summary of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Summary of Inventory" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Minimum Aggregate Future Loan Payments" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]", "terseLabel": "Schedule Of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r11", "r100", "r536", "r557" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r350", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Summary of Service Based Restricted Stock Units" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r353", "r364", "r366" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used in Applying Pricing Model" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r160", "r162", "r163", "r164", "r445", "r447" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk Percentage" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecurityDeposit": { "auth_ref": [ "r47" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.", "label": "Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "SecurityDeposit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureCashAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r74" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "totalLabel": "Selling, General and Administrative Expense, Total" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock (if converted) [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r96" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance and termination costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total", "verboseLabel": "Stock-based compensation expense related to stock options, restricted stock, shares issued and shares granted to non-employee directors" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockBasedCompensationExpenseDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Number of Shares, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted stock units outstanding", "verboseLabel": "Number of Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share", "terseLabel": "Weighted average grant date fair value, Amount per Share" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Granted", "verboseLabel": "Weighted average grant date fair value, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Number of Outstanding Shares, Ending Balance", "periodStartLabel": "Number of Outstanding Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance", "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Number of Shares, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted Average Grant Date Fair Value, Vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r371" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r372" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Expected volatility of underlying stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Number of Options, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Number of Options, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r357" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Aggregate number of stock granted to purchase", "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Number of Options, Granted", "verboseLabel": "Aggregate stock options granted to employees" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r355", "r377" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Number of Options, Outstanding, Ending balance", "periodStartLabel": "Number of Options, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted Average Exercise Price per Share, Outstanding, Ending balance", "periodStartLabel": "Weighted Average Exercise Price per Share, Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r348", "r352" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfServiceBasedRestrictedStockUnitsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted Average Exercise Price per Share, Granted", "verboseLabel": "Weighted average exercise price of options granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]", "terseLabel": "Vest on June 30, 2019 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]", "terseLabel": "Vest on March 24, 2020 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]", "terseLabel": "Vest on January 23, 2020 [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage", "terseLabel": "Vesting percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r369", "r383" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life of options", "verboseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureStockholdersDeficitEquitySummaryOfKeyAssumptionsUsedToValueWarrantDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAssumptionsUsedInApplyingPricingModelDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate Intrinsic Value, Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (In Years), Exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted Average Remaining Contractual Term (In Years), Outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r121" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r15", "r16", "r17", "r105", "r108", "r137", "r138", "r139", "r141", "r143", "r152", "r153", "r154", "r209", "r242", "r246", "r247", "r248", "r251", "r252", "r280", "r281", "r285", "r289", "r297", "r448", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r43", "r63", "r64", "r65", "r122", "r123", "r124", "r126", "r132", "r134", "r151", "r210", "r297", "r304", "r379", "r380", "r381", "r392", "r393", "r430", "r450", "r451", "r452", "r453", "r454", "r455", "r574", "r575", "r576", "r634" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r122", "r123", "r124", "r151", "r519" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureInventorySummaryOfInventoryDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r42", "r264", "r297", "r298", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "terseLabel": "Issuance of Series A Convertible Preferred Stock, net of commissions and beneficial conversion charge, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r17", "r297", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of shares under employee stock purchase plan, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Issuance of shares of common stock in lieu of board fees, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r16", "r17", "r297", "r304" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuance of common stock, Shares", "verboseLabel": "Issuance of common stock upon exercise of stock options, Share" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r297", "r304" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Exercise of stock options and vesting of restricted stock units, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r297", "r304", "r358" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Number of Options, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r43", "r297", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of Series A Convertible Preferred Stock, net of commissions and beneficial conversion charge, Value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r16", "r17", "r297", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of shares under employee stock purchase plan, Value" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Issuance of shares of common stock in lieu of board fees" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r16", "r17", "r297", "r304" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuance of common stock, Value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture", "terseLabel": "Exercise of stock options and vesting of restricted stock units, Value" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensationGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r108", "r194", "r209", "r448", "r483" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, Value", "periodStartLabel": "Beginning Balance, Value", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "http://www.epizyme.com/20220630/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit):" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r106", "r281", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r293", "r294", "r296", "r304", "r306" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' (Deficit) Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r456", "r484" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r456", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r456", "r484" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockholdersDeficitEquityAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r189", "r190", "r191", "r192", "r193", "r195" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r199", "r200", "r206", "r207", "r208", "r270", "r295", "r428", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r625", "r626", "r627", "r628", "r629", "r630", "r631" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/DisclosureCollaborationsAndLicensingAgreementsAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLongTermDebtAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSaleOfFutureRoyaltiesAdditionalInformationDetails", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureTheCompanyAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USTreasuryAndGovernmentMember": { "auth_ref": [ "r335", "r547", "r580" ], "lang": { "en-us": { "role": { "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).", "label": "US Treasury and Government [Member]", "terseLabel": "U.S. Government Agency Securities and U.S. Treasuries [Member]" } } }, "localname": "USTreasuryAndGovernmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfCompanySFinancialAssetsRecognizedAtFairValueDetail", "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesSummaryOfAvailableForSaleSecuritiesHeldDetail" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r112", "r335", "r343", "r547" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U S Treasury Securities Member" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r156", "r157", "r158", "r159", "r165", "r166", "r167" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r116", "r117", "r118", "r119", "r120" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureProductRevenueNetSummaryOfProductRevenueAllowanceAndReserveCategoriesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r469", "r475" ], "calculation": { "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLeasesSummaryOfLeaseCostsAndCompanySOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareCommonStockEquivalentsFromCalculationOfDilutedLossPerShareAttributableToCommonStockholdersDetail" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r136", "r143" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "verboseLabel": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_DisclosureLossPerShareScheduleOfBasicAndDilutedLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average common shares outstanding used in net loss per share attributable to common stockholders:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r135", "r143" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.epizyme.com/20220630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r121": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r149": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563" }, "r205": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r236": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r277": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "63", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r306": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r385": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r401": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r444": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r476": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r52": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r535": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r550": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(g)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "805", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=109242034&loc=d3e30696-158567" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column E)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column F)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611282-123010" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r604": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r620": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r621": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r622": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r623": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r624": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r625": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r626": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r627": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r628": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r629": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r630": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r631": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r632": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r633": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" } }, "version": "2.1" }